Simone B, De Stefano V, Leoncini E, Zacho J, Martinelli I, Emmerich J, et al. Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetetrahydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls. Eur J Epidemiol 2013;28:621–47.PubMedCrossrefGoogle Scholar
Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994;94:2521–4.PubMedCrossrefGoogle Scholar
Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64–7.CrossrefPubMedGoogle Scholar
Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. J Am Med Assoc 1997;277:1305–7.CrossrefGoogle Scholar
Thygesen LC, Ersboll AK. Danish population-based registers for public health and health-related welfare research: introduction to the supplement. Scand J Public Health 2011;39:8–10.PubMedCrossrefWeb of ScienceGoogle Scholar
Larsen TB, Lassen JF, Brandslund I, Byriel L, Petersen GB, Nørgaard-Pedersen B. The Arg506Gln mutation (FV Leiden) among a cohort of 4188 unselected Danish newborns. Thromb Res 1998;89:211–5.CrossrefPubMedGoogle Scholar
Herskovits AZ, Morgan EA, Lemire SJ, Lindeman NI, Dorfman DM. An improved algorithm for activated protein C resistance and factor V Leiden screening. Am J Clin Pathol 2013;140:379–86.Web of ScienceCrossrefPubMedGoogle Scholar
Sweeney JD, Blair AJ, King TC. Comparison of an activated partial thromboplastin time with a Russell viper venom time test in screening for factor V (Leiden) (FVR506Q). Am J Clin Pathol 1997;108:74–7.CrossrefPubMedGoogle Scholar
Strobl FJ, Hoffman S, Huber S, Williams EC, Voelkerding KV. Activated protein C resistance assay performance: improvement by sample dilution with factor V-deficient plasma. Arch Pathol Lab Med 1998;122:430–3.PubMedGoogle Scholar
Steinberg DM, Fine J, Chappell R. Sample size for positive and negative predictive value in diagnostic research using case-control designs. Biostatistics 2009;10:94–105.PubMedWeb of ScienceGoogle Scholar
Kristoffersen AH, Petersen PH, Rørass T, Sandberg S. Estimates of within-subject biological variation of protein C, antithrombin, protein S free, protein S activity, and activated protein C resistance in pregnant women. Clin Chem 2017;63:898–907.PubMedWeb of ScienceCrossrefGoogle Scholar
Rühl H, Schröder L, Müller J, Sukhitashvili S, Welz J, Kuhn WC, et al. Impact of hormone-associated resistance to activated protein C on the thrombotic potential of oral contraceptives: a prospective observational study. PLoS One 2014;9:e105007.CrossrefWeb of SciencePubMedGoogle Scholar
Johnson KC, Aragaki AK, Jackson R, Reiner A, Sandset PM,Rosing J, et al. Tissue factor pathway inhibitor, activated protein C resistance, and risk of coronary heart disease due to combined estrogen plus progestin therapy. Arterioscler Thromb Vasc Biol 2016;36:418–24.Web of ScienceCrossrefPubMedGoogle Scholar
Gouault-Heilmann M, Leroy-Matheron C. Factor V Leiden-dependent APC resistance: improved sensitivity and specificity of the APC resistance test by plasma dilution in factor V-depleted plasma. Thromb Res 1996;82:281–3.CrossrefPubMedGoogle Scholar
About the article
Published Online: 2019-03-23
Published in Print: 2019-07-26
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
Conflict of interest: None declared.